|
Fördröjd
Canadian Securities Exchange
20.00.56 2026-09-11
|
5-dagars förändring | Förändring 1 jan. | ||
| 0,6000 CAD | +1,69 % |
|
−4,76 % | −14,29 % |
| 09-08 | Grown Rogue International inleder odling vid anläggning i Fridley, Minnesota | CI |
| 08-21 | Grown Rogue stiger 13 procent efter besked om nytt dotterbolag för förvärv i New York | MT |
Försäljning 2025 per affärssegment
Försäljning 2025 efter Geografi
Historisk fördelning av intäkter per affärssegment
Net Income: Fördelning efter verksamhetssegment
Historik över geografisk fördelning av omsättning
| Skatteperiod: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | |||||||||
New Jersey | - | - | - | - | 11,34 mn | ||||
Interest Expense | - | - | - | - | −130 tn | ||||
Income Tax Expense | - | - | - | - | 119 tn | ||||
EBT | - | - | - | - | 4,63 mn | ||||
Gross Profit | - | - | - | - | 6,06 mn | ||||
EBITDA | - | - | - | - | 6,02 mn | ||||
D&A | - | - | - | - | 244 tn | ||||
Net Income | - | - | - | - | 4,51 mn | ||||
Oregon | - | - | 11 mn | 12,09 mn | 11,06 mn | ||||
Total Assets | - | - | 6,64 mn | - | - | ||||
Interest Expense | - | - | - | - | −10 tn | ||||
EBT | - | - | - | - | 481 tn | ||||
Gross Profit | - | - | 4,62 mn | 5,18 mn | 3,16 mn | ||||
EBITDA | - | - | - | - | 1,16 mn | ||||
D&A | - | - | - | - | 213 tn | ||||
Net Income | - | - | - | - | 481 tn | ||||
| - | - | - | - | 10,03 mn | |||||
Michigan | - | - | 11,42 mn | 12,94 mn | 10,03 mn | ||||
Total Assets | - | - | 4,02 mn | - | - | ||||
Interest Expense | - | - | - | - | −14,13 tn | ||||
Income Tax Expense | - | - | - | - | −104 tn | ||||
EBT | - | - | - | - | 2,31 mn | ||||
Gross Profit | - | - | 6,65 mn | 6,48 mn | 4,93 mn | ||||
EBITDA | - | - | - | - | 3,38 mn | ||||
D&A | - | - | - | - | 185 tn | ||||
Net Income | - | - | - | - | 2,42 mn | ||||
| - | - | - | - | 11,34 mn | |||||
| - | - | - | - | 11,06 mn | |||||
Consulting Services | |||||||||
Corporate | - | - | 929 tn | 1,99 mn | - | ||||
Interest Expense | - | - | - | - | −1,23 mn | ||||
Income Tax Expense | - | - | - | - | 1,59 mn | ||||
EBT | - | - | - | - | −2,59 mn | ||||
Gross Profit | - | - | 620 tn | 1,78 mn | - | ||||
EBITDA | - | - | - | - | −5,17 mn | ||||
D&A | - | - | - | - | 60,07 tn | ||||
Net Income | - | - | - | - | −4,18 mn | ||||
Total Assets | - | - | 1,36 mn | - | - | ||||
Medicinal Chemicals and Botanical Products | |||||||||
Pharmaceuticals | 9,38 mn | 17,76 mn | - | - | - | ||||
Total Assets | 14,21 mn | 16,37 mn | - | - | - | ||||
Interest Expense | −1,15 mn | −894 tn | - | - | - | ||||
Income Tax Expense | 151 tn | 245 tn | - | - | - | ||||
CAPEX | −2,05 mn | −1,11 mn | - | - | - | ||||
EBT | −864 tn | 665 tn | - | - | - | ||||
Gross Profit | 6,1 mn | 8,12 mn | - | - | - | ||||
D&A | 185 tn | 751 tn | - | - | - | ||||
Operating Income | 702 tn | 957 tn | - | - | - | ||||
Net Income | −2,41 mn | 447 tn | - | - | - |
| Skatteperiod: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
United States | 9,38 mn | 17,76 mn | 23,35 mn | 27,02 mn | 32,43 mn | ||||
Total Assets | 14,21 mn | 16,37 mn | 30,16 mn | 43,32 mn | 62,74 mn | ||||
Interest Expense | −1,15 mn | −894 tn | −1,4 mn | −2,42 mn | −1,38 mn | ||||
Income Tax Expense | 151 tn | 245 tn | 371 tn | 1,7 mn | 1,6 mn | ||||
D&A | 185 tn | 751 tn | 579 tn | 940 tn | 702 tn | ||||
CAPEX | −2,05 mn | −1,11 mn | −1,46 mn | −1,74 mn | −4,66 mn | ||||
Gross Profit | 6,1 mn | 8,12 mn | 12,67 mn | 13,44 mn | 14,15 mn | ||||
Net Income | −2,41 mn | 447 tn | −533 tn | −11,3 mn | 1,73 mn | ||||
EBT | −864 tn | 665 tn | −291 tn | −9 mn | 4,83 mn | ||||
Operating Income | 702 tn | 957 tn | 4,25 mn | 1,12 mn | −593 tn |
Välj din utgåva
All finansiell information anpassad till den nationella nivån
